Risk factors for autonomic and somatic nerve dysfunction in different stages of glucose tolerance

Journal of Diabetes and its Complications

Volumn 31, Issue 3, 2017, Pages 537-543

  Dimova, Rumyana ^a   Tankova, Tsvetalina ^a   Guergueltcheva, Velina ^b   Tournev, Ivailo ^a   Chakarova, Nevena ^a   Grozeva, Greta ^a   Dakovska, Lilia ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

Author keywords

Cardiovascular autonomic; Diabetic sensory polyneuropathy; Glucose tolerance; Sensory neuropathy

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

ABDOMINAL OBESITY; ADULT; AGE; ARTICLE; AUTONOMIC NERVE; AUTONOMIC NEUROPATHY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ELECTRONEUROGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; GLYCATION; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYNEUROPATHY; PRIORITY JOURNAL; QTC INTERVAL; RISK ASSESSMENT; SENSORY NEUROPATHY; SYMPATHETIC TONE; WAIST CIRCUMFERENCE; ADRENERGIC SYSTEM; AGED; AUTONOMIC NERVOUS SYSTEM; BODY MASS; BULGARIA; CHOLINERGIC SYSTEM; COMPARATIVE STUDY; COMPLICATION; DIABETIC NEUROPATHY; PATHOPHYSIOLOGY; PREVALENCE; RISK FACTOR; UNIVERSITY HOSPITAL;

ADULT; AGED; AUTONOMIC NERVOUS SYSTEM; AUTONOMIC NERVOUS SYSTEM DISEASES; BODY MASS INDEX; BULGARIA; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; FEMALE; GLUCOSE INTOLERANCE; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; OBESITY, ABDOMINAL; PARASYMPATHETIC NERVOUS SYSTEM; POLYNEUROPATHIES; PREDIABETIC STATE; PREVALENCE; RISK FACTORS; SYMPATHETIC NERVOUS SYSTEM; WAIST CIRCUMFERENCE;

EID: 85007388220     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2016.11.002     Document Type: Article

References (76)

1. AANEM, Proper performance and interpretation of electrodiagnostic studies. [Corrected]. Muscle & Nerve 51:3 (2015), 468–471.
2. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein, H.C., Miller, M.E., Byington, R.P., Goff, D.C. Jr., Bigger, J.T.,.. Friedewald, W.T., Effects of intensive glucose lowering in type 2 diabetes. The New England Journal of Medicine 358:24 (2008), 2545–2559.
3. ADVANCE Collaborative Group, Patel, A., MacMahon, S., Chalmers, J., Neal, B., Billot, L.,.. Travert, F., Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine 358:24 (2008), 2560–2572.
4. Araújo, F., Antelmi, I., Pereira, A.C., Latorre Mdo, R., Grupi, C.J., Krieger, J.E., Mansur, A.J., Lower heart rate variability is associated with higher serum high-sensitivity C-reactive protein concentration in healthy individuals aged 46 years or more. International Journal of Cardiology 107:3 (2006), 333–337.
5. Arora, R.R., Aysin, E., Aysin, B., et al. Therapeutic implications of sympathetic stimulus in orthostatic patients: Measured by spectral domain analysis. 2007, AHA Scientific Sessions, Orlando, FL.
6. Aso, Y., Wakabayashi, S., Nakano, T., Yamamoto, R., Takebayashi, K., Inukai, T., High serum high-sensitivity C-reactive protein concentrations are associated with relative cardiac sympathetic overactivity during the early morning period in type 2 diabetic patients with metabolic syndrome. Metabolism 55:8 (2006), 1014–1021.
7. Barr, E.L., Wong, T.Y., Tapp, R.J., Harper, C.A., Zimmet, P.Z., Atkins, R.,.. AusDiab Steering Committee, Is peripheral neuropathy associated with retinopathy and albuminuria in individuals with impaired glucose metabolism? The 1999–2000 AusDiab study. Diabetes Care 29 (2006), 1114–1116.
8. Beske, S.D., Alvarez, G.E., Ballard, T.P., et al. Reduced cardiovagal baroreflex gain in visceral obesity: implications for the metabolic syndrome. American journal of physiology. Heart and circulatory physiology 282 (2002), 630–635.
9. Bongaerts, B.W.C., Rathmann, W., Kowall, B., Herder, C., Stockl, D., Meisinger, C., Ziegler, D., Older subjects with diabetes and prediabetes are frequently unaware of having distal sensorimotor polyneuropathy. The KORA F4 study. Diabetes Care 36 (2013), 1141–1146.
10. Boulton, A.J., Vinik, A.I., Arezzo, J.C., Bril, V., Feldman, E.L., Freeman, R.,.. American Diabetes Association, Diabetic neuropathies: A statement by the American Diabetes Association. Diabetes Care 28:4 (2005), 956–962.
11. Callaghan, B.C., Little, A.A., Feldman, E.L., Hughes, R.A., Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database of Systematic Reviews, 6, 2012 Jun 13, CD007543, 10.1002/14651858.
12. Callaghan, B.C., Xia, R., Banerjee, M., de Rekeneire, N., Harris, T.B., Newman, A.B.,.. for the Health ABC study, Metabolic syndrome components are associated with symptomatic polyneuropathy independent of glycemic status. Diabetes Care, 2016, 10.2337/dc16-0081.
13. Christou, D.D., Jones, P.P., Pimentel, A.E., et al. Increased abdominal-to-peripheral fat distribution contributes to altered autonomic-circulatory control with human aging. The American Journal of Physiology 287 (2004), 1530–1537.
14. Cox, A.J., Azeem, A., Yeboah, J., Soliman, E.Z., Aggarwal, S.R., Bertoni, A.G.,.. Bowden, D.W., Heart rate-corrected QT interval is an independent predictor of all-cause and cardiovascular mortality in individuals with type 2 diabetes: The Diabetes Heart Study. Diabetes Care 37:5 (2014), 1454–1461.
15. Damodaran, A., Kabal, B., Autonomic dysfunction in central obesity. World Journal of Medical Sciences 8 (2013), 118–122.
16. Davis, T.M., Yeap, B.B., Davis, W.A., Bruce, D.G., Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: The Fremantle Diabetes Study. Diabetologia 51:4 (2008), 562–566.
17. DECODE Study Group, Glucose tolerance and cardio-vascular mortality: Comparison of fasting and 2-hour diagnostic criteria. Archives of Internal Medicine 161 (2001), 397–405.
18. DECODE Study Group, Is the current definition for the diabetes relevant to mortality risk from all causes and cardiovascular and non-cardiovascular diseases?. Diabetes Care 26 (2003), 688–696.
19. DePace, N.L., Mears, J.P., Yayac, M., Colombo, J., Cardiac autonomic testing and treating heart disease. A clinical perspective. Heart International 9:2 (2014), 45–52.
20. Di Flaviani, A., Picconi, F., Di Stefano, P., Giordani, I., Malandrucco, I., Maggio, P.,.. Frontoni, S., Impact of glycemic and blood pressure variability on surrogate measures of cardiovascular outcomes in type 2 diabetic patients. Diabetes Care 34:7 (2011), 1605–1609.
21. Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P.D.,.. VADT Investigators, Glucose control and vascular complications in veterans with type 2 diabetes. The New England Journal of Medicine 360:2 (2009), 129–139.
22. Duksal, T., Tiftikcioglu, B.I., Bilgin, S., Kose, S., Zorlu, Y., Role of inflammation in sensory neuropathy in prediabetes or diabetes. Acta Neurologica Scandinavica, 2015, 10.1111/ane.12474 (Epub ahead of print).
23. Ellenberg, M., Diabetic neuropathy presenting as the initial clinical manifestation of diabetes. Annals of Internal Medicine 49 (1958), 620–631.
24. England, J.D., Gronseth, G.S., Franklin, G., et al. Evaluation of distal symmetric polyneuropathy: Role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Practice Parameter. Report of the American Academy of Neurology, American Association of Neuro-Muscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine And Rehabilitation. Neurology 72 (2009), 177–184.
25. Farah, B.Q., do Prado, W.L., Tenório, T.R., Ritti-Dias, R.M., Heart rate variability and its relationship with central and general obesity in obese normotensive adolescents. Einstein (Sao Paulo) 11 (2013), 285–290.
26. Fiorentini, A., Perciaccante, A., Valente, R., Paris, A., Serra, P., Tubani, L., The correlation among QTc interval, hyperglycaemia and the impaired autonomic activity. Autonomic Neuroscience: Basic and Clinical 154 (2010), 94–98.
27. Fleischer, J., Diabetic autonomic imbalance and glycemic variability. Journal of Diabetes Science and Technology 6:5 (2012), 1207–1215.
28. Foss, C.H., Vestbo, E., Frøland, A., Gjessing, H.J., Mogensen, C.E., Damsgaard, E.M., Autonomic neuropathy in nondiabetic offspring of type 2 diabetic subjects is associated with urinary albumin excretion rate and 24-h ambulatory blood pressure: the Fredericia study. Diabetes 50:3 (2001), 630–636.
29. Franklin, G.M., Shetterly, S.M., Cohen, J.A., Baxter, J., Hamman, R.F., Risk factors for distal symmetric neuropathy in NIDDM: The San Luis Valley Diabetes Study. Diabetes Care 17 (1994), 1172–1177.
30. Fraser, D.M., Campbell, I.W., Ewing, D.J., et al. Peripheral and autonomic nerve function in newly diagnosed diabetes mellitus. Diabetes 26:6 (1977), 546–550.
31. Gaede, P., Vedel, P., Larsen, N., Jensen, G.V.H., Parving, H.H., Pedersen, O., Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. The New England Journal of Medicine 348 (2003), 383–393.
32. Gerritsen, J., Dekker, J.M., TenVoorde, B.J., et al. Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: The Hoorn Study. Diabetes Care 24:10 (2001), 1793–1798.
33. Green, A.Q., Krishnan, S., Finucane, F.M., Rayman, G., Altered C-fiber function as an indicator of early peripheral neuropathy in individuals with impaired glucose tolerance. Diabetes Care 33:1 (2010), 174–176.
34. Hemingway, H., Shipley, M., Brunner, E., et al. Does autonomic function link social position to coronary risk? The Whitehall II study. Circulation 111 (2005), 3071–3077.
35. Herder, C., Lankisch, M., Ziegler, D., Rathmann, W., Koenig, W., Illig, T.,.. Meisinger, C., Subclinical inflammation and diabetic polyneuropathy: MONICA/KORA Survey F3 (Augsburg, Germany). Diabetes Care 32:4 (2009), 680–682.
36. Hughes, R.A., Umapathi, T., Gray, I.A., Gregson, N.A., Noori, M., Pannala, A.S.,.. Swan, A.V., A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy. Brain 127 (2004), 1723–1730.
37. Istenes, I., Keresztes, K., Hermányi, Z., Putz, Z., Vargha, P., Gandhi, R.,.. Kempler, P., Relationship between autonomic neuropathy and hypertension – are we underestimating the problem?. Diabetic Medicine 25:7 (2008), 863–866.
38. Jarczok, M.N., Koenig, J., Mauss, D., Fischer, J.E., Thayer, J.F., Lower heart rate variability predicts increased level of C-reactive protein 4 years later in healthy, nonsmoking adults. Journal of Internal Medicine 276:6 (2014), 667–671.
39. Kannan, M.A., Sarva, S., Kandadai, R.M., Paturi, V.R., Jabeen, S.A., Borgohain, R., Prevalence of neuropathy in patients with impaired glucose tolerance using various electrophysiological tests. Neurology India 62:6 (2014), 656–661.
40. Katon, J.G., Reiber, G.E., Nelson, K.M., Peripheral neuropathy defined by monofilament insensitivity and diabetes status: NHANES 1999–2004. Diabetes Care 36 (2013), 1604–1606.
41. Koskinen, T., Kähönen, M., Jula, A., et al. Metabolic syndrome and short-term heart rate variability in young adults: The cardiovascular risk in young Finns study. Diabetic Medicine 26 (2009), 354–361.
42. Laederach-Hofmann, K., Mussgay, L., Ruddel, H., Autonomic cardiovascular regulation in obesity. The Journal of Endocrinology 164 (2000), 59–66.
43. Laitinen, T., Lindström, J., Eriksson, J., Ilanne-Parikka, P., Aunola, S., Keinänen-Kiukaanniemi, S., et al. Cardiovascular autonomic dysfunction is associated with central obesity in persons with impaired glucose tolerance. Diabetic Medicine 28:6 (2011), 699–704.
44. Lee, C.C., Perkins, B.A., Kayaniyil, S., Harris, S.B., Retnakaran, R., Gerstein, H.C.,.. Hanley, A.J., Peripheral neuropathy and nerve dysfunction in individuals at high risk for type 2 diabetes: The PROMISE cohort. Diabetes Care 38:5 (2015), 793–800.
45. Lehtinen, J.M., Uusitupa, M., Siitonen, O., Pyorala, K., Prevalence of neuropathy in newly diagnosed NIDDM and nondiabetic control subjects. Diabetes 38 (1989), 1308–1313.
46. Lindmark, S., Lönn, L., Wiklund, U., Tufvesson, M., Olsson, T., Eriksson, J.W., Dysregulation of the autonomic nervous system can be a link between visceral adiposity and insulin resistance. Obesity Research 13:4 (2005), 717–728.
47. Lu, B., Hu, J., Wen, J., Zhang, Z., Zhou, L., Li, Y., Hu, R., Determination of peripheral neuropathy prevalence and associated factors in Chinese subjects with diabetes and pre-diabetes – ShangHai Diabetic neuRopathy Epidemiology and Molecular Genetics Study (SH-DREAMS). PLoS One, 8(4), 2013, e61053.
48. Meerwaldt, R., Links, T.P., Graaff, R., Hoogenberg, K., Lefrandt, J.D., Baynes, J.W.,.. Smit, A.J., Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy. Diabetologia 48:8 (2005), 1637–1644.
49. Meyer, C., Milat, F., McGrath, B.P., Cameron, J., Kotsopoulos, D., Teede, H.J., Vascular dysfunction and autonomic neuropathy in type 2 diabetes. Diabetic Medicine 21:7 (2004), 746–751.
50. Min, K., Min, J.Y., Paek, D., Cho, S.I., The impact of the components of metabolic syndrome on heart rate variability: Using the NCEP-ATP III and IDF definitions. PACE – Pacing and Clinical Electrophysiology 31 (2008), 584–591.
51. Mulder, D.J., Water, T.V., Lutgers, H.L., et al. Skin autoflourescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: An overview of current clinical studies, evidence, and limitations. Diabetes Technology & Therapeutics 8:5 (2008), 523–535.
52. Nang, E.E., Khoo, C.M., Tai, E.S., Lim, S.C., Tavintharan, S., Wong, T.Y.,.. Lee, J., Is there a clear threshold for fasting plasma glucose that differentiates between those with and without neuropathy and chronic kidney disease? The Singapore Prospective Study Program. American Journal of Epidemiology 169:12 (2009), 1454–1462.
53. Pop-Busui, R., Evans, G.W., Gerstein, H.C., Fonseca, V., Fleg, J.L.,.. Prineas, R., Action to Control Cardiovascular Risk in Diabetes Study Group, Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 33:7 (2010), 1578–1584.
54. Rana, B.S., Lim, P.O., Naas, A.A., Ogston, S.A., Newton, R.W.,.. Struthers, A.D., QT interval abnormalities are often present at diagnosis in diabetes and are better predictors of cardiac death than ankle brachial pressure index and autonomic function tests. Heart 91:1 (2005), 44–50.
55. Sahin, S., Karsidag, S., Ayalp, S., Sengul, A., Us, O., Karsidag, K., Determination of nerve conduction abnormalities in patients with impaired glucose tolerance. Neurological Sciences 30:4 (2009), 281–289.
56. Singleton, J.R., Smith, A.G., Bromberg, M.B., Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care 24:8 (2001), 1448–1453.
57. Skyler, J., Diabetic complications: The importance of glucose control. Endocrinology and Metabolism Clinics of North America 25 (1996), 243–254.
58. Smulders, Y.M., Jager, A., Gerritsen, J., et al. Cardiovascular autonomic function is associated with (micro-)albuminuria in elderly Caucasian subjects with impaired glucose tolerance or type 2 diabetes: The Hoorn study. Diabetes Care 23:9 (2000), 1369–1374.
59. Soares-Miranda, L., Sandercock, G., Vale, S., et al. Metabolic syndrome, physical activity and cardiac autonomic function. Diabetes/Metabolism Research and Reviews 28 (2012), 363–369.
60. Spallone, V., Ziegler, D., Freeman, R., Bernardi, L., Frontoni, S., Pop-Busui, R.,.. Valensi, P., Toronto Consensus Panel on Diabetic Neuropathy, Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes/Metabolism Research and Reviews 27:7 (2011), 639–653.
61. Stein, P.K., Barzilay, J.I., Chaves, P.H., Traber, J., Domitrovich, P.P., Heckbert, S.R., Gottdiener, J.S., Higher levels of inflammation factors and greater insulin resistance are independently associated with higher heart rate and lower heart rate variability in normoglycemic older individuals: The Cardiovascular Health study. Journal of the American Geriatrics Society 56:2 (2008), 315–321.
62. Sugisawa, E., Miura, J., Iwamoto, Y., Uchigata, Y., Skin auto-fluorescence reflects integration of past long-term glycemic control in patients with type 1 diabetes. Diabetes Care 36:8 (2013), 2339–2345.
63. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology, Heart rate variability, standards of measurement, physiological interpretation, and clinical use. Circulation 93 (1996), 1043–1065.
64. Tesfaye, S., Boulton, A.J., Dyck, P.J., Freeman, R., Horowitz, M., Kempler, P.,.. Valensi, P., Toronto Diabetic Neuropathy Expert Group, Diabetic neuropathies: Update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 33 (2010), 2285–2293.
65. Tesfaye, S., Chaturvedi, N., Eaton, S.E., Ward, J.D., Manes, C., Ionescu-Tirgoviste, C.,.. Fuller, J.H., EURODIAB Prospective Complications Study Group, Vascular risk factors and diabetic neuropathy. The New England Journal of Medicine 352 (2005), 341–350.
66. UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:9131 (1998), 837–853.
67. Vinik, A.I., Ziegler, D., Diabetic cardiovascular autonomic neuropathy. Circulation 115 (2007), 387–397.
68. Vinik, A.I., Aysin, B., Colombo, J., Differentiation of autonomic dysfunction by enhanced frequency domain analysis reveals additional stages in the progression of autonomic decline in diabetics. 5th Annual Diabetes Technology Meeting. San Francisco, CA, 10–12 November 2005, 2005.
69. Vinik, A.I., Erbas, T., Casellini, C.M., Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease. Journal of Diabetes Investigation 4:1 (2013), 4–18.
70. Wada, R., Yagihashi, S., Role of advanced glycation end products and their receptors in development of diabetic neuropathy. Annals of the New York Academy of Sciences 1043 (2005), 598–604.
71. Windham, B.G., Fumagalli, S., Ble, A., et al. The relationship between heart rate variability and adiposity differs for central and overall adiposity. Journal of Obesity, 2012, 2012, 149516.
72. Wu, J.S., Yang, Y.C., Lin, T.S., et al. Epidemiological evidence of altered cardiac autonomic function in subjects with impaired glucose tolerance but not isolated fasting plasma glucose. The Journal of Clinical Endocrinology and Metabolism 92 (2007), 3885–3889.
73. Young, L.H., Wackers, F.J.T., Chyun, D.A., et al., Investigators, D.I.A.D., Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: The DIAD study: A randomized controlled trial. JAMA 301 (2009), 1547–1555.
74. Ziegler, D., Rathmann, W., Dickhaus, T., Meisinger, C., Mielck, A., KORA Study Group, Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy. The MONICA/KORA Augsburg surveys S2 and S3. Diabetes Care 31 (2008), 464–469.
75. Ziegler, D., Voss, A., Rathmann, W., Strom, A., Perz, S., Roden, M.,.. KORA Study Group, Increased prevalence of cardiac autonomic dysfunction at different degrees of glucose intolerance in the general population: The KORA S4 survey. Diabetologia 58:5 (2015), 1118–1128.
76. Ziegler, D., Zentai, C.P., Perz, S., Rathmann, W., Haastert, B., Döring, A.,.. KORA Study Group, Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population: The MONICA/KORA Augsburg cohort study. Diabetes Care 31:3 (2008), 556–561.